Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1788494 | 0.82 | CA1 (0.39) | CA1CA2CA9 | |
| SCHEMBL576038 | 0.78 | CA1 (0.36) | CA1CA2CA9 | |
| SCHEMBL575836 | 0.78 | CA1 (0.40) | CA1CA2CA9 | |
| SCHEMBL15352856 | 0.77 | CA1 (0.33) | CA1CA2CA9 | |
| SCHEMBL9379955 | 0.77 | CA1 (0.33) | CA1CA2CA9 | |
| SCHEMBL777309 | 0.77 | CA1 (0.33) | CA1CA2CA9 | |
| SCHEMBL29404156 | 0.73 | CA1 (0.32) | CA1CA2CA9 | |
| SCHEMBL4371897 | 0.73 | — | — | |
| SCHEMBL2058098 | 0.73 | CA1 (0.41) | CA1CA2CA9 | |
| SCHEMBL30503504 | 0.73 | CA1 (0.31) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107146911-A | The application of lithium ion battery, nonaqueous lithium ion battery electrolyte and flurosulphonic acid acid anhydride in nonaqueous lithium ion battery electrolyte is prepared | 珠海市赛纬电子材料股份有限公司 | 2017-09-08 | — | — | CN | claimed |
| WO-2009073426-A2 | FLUORINATED ALKANESULFONIC ACID ANHYDRIDES AND PROCESSES FOR MAKING THE SAME | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-06-11 | — | — | WO | claimed |
| US-20090137840-A1 | Fluorinated Alkanesulfonic Acid Anhydrides and Processes for Making the Same | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-05-28 | — | — | US | claimed |
| WO-2025036442-A1 | METHOD FOR PREPARING PYRAZINONAPHTHYRIDINE DIONE COMPOUND, AND INTERMEDIATE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-02-20 | — | — | WO | disclosed |
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| US-11817546-B2 | Lithium ion secondary battery | NEC CORPORATION (JP) | 2023-11-14 | — | — | US | disclosed |
| US-11616253-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-03-28 | — | — | US | disclosed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
| US-20220278370-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-09-01 | — | — | US | disclosed |
| US-11367899-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-06-21 | — | — | US | disclosed |
| US-11251424-B2 | Lithium ion secondary battery | NEC CORPORATION (JP) | 2022-02-15 | — | — | US | disclosed |
| EP-1237874-B1 | SELECTIVE NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2006-02-22 | — | — | EP | disclosed |
| US-6635630-B2 | Respiratory system disorders; antiinflammatory agents | SCHERING CORPORATION | 2003-10-21 | — | — | US | disclosed |
| US-20030064980-A1 | Selective neurokinin antagonists | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
| EP-1237874-A2 | SELECTIVE NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020123491-A1 | SELECTIVE NEUROKININ ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2002-09-05 | — | — | US | disclosed |
| US-6436928-B1 | IN COMBINATION WITH A SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SUBSTITUTED CYCLIC UREAS (IMIDAZOLIDINONES); ANTAGONISTS OF TACHYKININ RECEPTORS, IN PARTICULAR AS ANTAGONISTS OF THE NEUROPEPTIDES NEUROKININ-1 RECEPTOR (NK.SUB.1). | SCHERING CORPORATION | 2002-08-20 | — | — | US | disclosed |
| WO-2001044200-A2 | SELECTIVE NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 2001-06-21 | — | — | WO | disclosed |
| US-5821357-A | REACTING ALPHA-ANOMER ENRICHED 2,2-DIFLUOROCARBOHYDRATE WITH AT LEAST TWO MOLAR EQUIVALENTS OF METAL DERIVATIVE OF NUCLEOBASE IN LOW FREEZING INERT SOLVENT | ELI LILLY AND COMPANY (US) | 1998-10-13 | — | — | US | disclosed |
| US-5571917-A | Taxoid intermediates | RHONE-POULENC RORER S.A. (FR) | 1996-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | CA1 1429/4885CA2 513/4885CA9 2574/4885 |
| US-20020123491-A1 | SELECTIVE NEUROKININ ANTAGONISTS | CRHR1, CNR1, CRHR2 | CA1 2422/4885CA2 920/4885CA9 1691/4885 |
| US-20030064980-A1 | Selective neurokinin antagonists | CRHR1, CNR1, CRHR2 | CA1 2318/4885CA2 1051/4885CA9 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.